Listen
REVESTIVE (teduglutide), synthetic GLP-2 analogue
GASTROENTEROLOGY - New medicinal product
Opinions on drugs -
Posted on
Jun 02 2015
Reason for request
Inclusion
Moderate improvement in the treatment of patients with short bowel syndrome who have been receiving parenteral nutrition for several months.
- REVESTIVE has Marketing Authorisation in the treatment of short bowel syndrome in adults. Patients should be stable following a period of intestinal adaptation after surgery.
- Its efficacy versus placebo in reducing the volume of parenteral nutrition necessary was at least 20% after 24 weeks. The level of evidence of the demonstration of efficacy is low.
- Despite the lack of long-term efficacy and safety data and taking into account its efficacy in reducing the need for parenteral nutrition, in the absence of a therapeutic alternative, REVESTIVE provides a moderate therapeutic benefit in the treatment of short bowel syndrome in patients who have been receiving parenteral nutrition for several months.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| moderate |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
